The standard treatment for mild asthma in children—relying on quick-relief inhalers like albuterol—is being challenged by emerging research suggesting a different approach could be more effective. A recent study, published in The Lancet Respiratory Medicine, investigated what’s known as “anti-inflammatory reliever” (AIR) therapy, and while the initial findings are promising, significant questions remain about its widespread implementation, particularly in younger children. This shift in thinking around asthma treatment in children is prompting a reevaluation of long-held practices and a call for further investigation.
For decades, the head-to treatment for episodic asthma symptoms has been short-acting beta2-agonists (SABAs) like albuterol, which quickly open airways. However, frequent SABA utilize has been linked to worsening asthma control and increased risk of severe exacerbations. AIR therapy proposes a different strategy: using a low-dose inhaled corticosteroid (ICS) as a daily reliever, rather than reserving it for persistent symptoms. The goal is to address the underlying inflammation driving the asthma, rather than just treating the symptoms as they arise.
The CARE study, a randomized controlled trial involving 633 school-age children and adolescents (ages 5-18) with mild asthma, compared AIR therapy (using budesonide as the ICS) to as-needed salbutamol (albuterol). Researchers found that AIR therapy resulted in a 33% reduction in severe exacerbations requiring oral corticosteroids, a key measure of asthma control. The study, led by Dr. Jonathan Price at the University of Nottingham, also showed a trend towards fewer asthma-related hospitalizations, though this difference wasn’t statistically significant.
The Promise and Practicalities of AIR Therapy
The potential benefits of AIR therapy are clear: reducing inflammation could lead to better long-term asthma control and fewer serious events. However, translating these findings into clinical practice isn’t straightforward. One major concern is the age range studied. The CARE trial focused on school-age children and adolescents, leaving a gap in knowledge about the safety and efficacy of AIR therapy in preschool-aged children, who often experience different asthma triggers and have smaller airways.
“We need to be cautious about extrapolating these results to highly young children,” explains Dr. Emily Carter, a pediatric pulmonologist at Boston Children’s Hospital, who was not involved in the CARE study. “Their airways are still developing, and the potential long-term effects of regular ICS exposure are less well understood in this age group.” The use of inhaled corticosteroids, even at low doses, carries potential side effects, including slowed growth, though studies suggest this effect is minimal with appropriate monitoring. The American Academy of Allergy, Asthma & Immunology (AAAAI) provides detailed information on ICS use and potential side effects.
Another practical hurdle is adherence. AIR therapy requires a shift in mindset for both patients and healthcare providers. Instead of reaching for the blue reliever inhaler at the first sign of symptoms, patients need to consistently use the ICS reliever, even when they feel relatively well. This requires education and ongoing support to ensure proper technique and understanding of the treatment plan.
Unanswered Questions and Ongoing Research
Beyond age-specific considerations, several other questions remain. The CARE study used budesonide, a specific ICS. It’s unclear whether the same benefits would be observed with other ICS medications. The study didn’t investigate the optimal dose of ICS for AIR therapy, or the best way to tailor treatment to individual patients.
Researchers are also exploring the role of biomarkers in identifying patients who are most likely to benefit from AIR therapy. Measuring airway inflammation could help personalize treatment and avoid unnecessary ICS exposure in children who don’t need it. The use of fractional exhaled nitric oxide (FeNO) testing, which measures airway inflammation, is gaining traction as a potential tool for guiding AIR therapy decisions.
The study also didn’t address the cost-effectiveness of AIR therapy. While ICS medications are generally affordable, the cost of regular monitoring and potential side effect management needs to be considered.
What In other words for Families and Healthcare Providers
The CARE study represents a significant step forward in our understanding of asthma management in children. However, it’s not a call to immediately switch all patients to AIR therapy. Instead, it’s a signal to re-evaluate current practices and consider AIR therapy as a potential option for select patients, particularly those with frequent SABA use and persistent symptoms.
For families, the key takeaway is to have an open conversation with their child’s healthcare provider about the potential benefits and risks of AIR therapy. It’s significant to discuss individual asthma triggers, symptom patterns, and any concerns about medication side effects.
Healthcare providers need to stay informed about the latest research on AIR therapy and be prepared to educate patients and families about this new approach. Ongoing monitoring and individualized treatment plans are essential to ensure optimal asthma control and minimize potential risks.
Further research is crucial to address the remaining unanswered questions and refine the implementation of AIR therapy in children. Several ongoing clinical trials are investigating the efficacy of AIR therapy in different age groups and with different ICS medications. The results of these studies will help to inform clinical guidelines and optimize asthma care for children worldwide.
The next major update on this evolving field is expected at the American Thoracic Society International Conference in May 2024, where researchers will present new data on AIR therapy and its potential applications.
Do you have questions about asthma management or AIR therapy? Share your thoughts in the comments below, and please share this article with anyone who might identify it helpful.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Related reading
